Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag A new two-monthly HIV prevention injection, cabotegravir, is recommended for NHS use in England and Wales to help end new HIV cases by 2030.

flag A long-acting injectable HIV prevention drug, cabotegravir (Apretude), has been recommended for use on the NHS in England and Wales, offering a two-monthly alternative to daily oral PrEP. flag The treatment is for adults and adolescents at high risk of HIV who face barriers to daily pills due to medical, lifestyle, or social challenges. flag Approved by NICE, it will be available through sexual health clinics, with rollout expected within months. flag The NHS secured a discount on the drug, which has a list price of about £7,000 per year. flag Officials say it could help the UK reach its goal of ending new HIV transmissions by 2030. flag While PrEP use in England rose to 111,000 people in 2024, disparities persist, especially among Black African heterosexual men and women. flag Advocates urge rapid expansion beyond clinics to improve equity. flag The injection must be used with safer sex practices. flag Early research suggests future annual options may be possible.

29 Articles